Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by balmusetteon Oct 14, 2021 11:15am
199 Views
Post# 34005181

RE:For French speaking folks

RE:For French speaking folks The article is based on an interview given by Paul Levesque to La Presse newspaper.
Must of the stuff discussed in it is already known by this board.

It is a good article,honest and upbeat; it reflects the enthousiastic mood Paul Levesque seems to be in when he discusses TH's cancer program and Nash. He uses words like ''spectacular '' , seldom seen''. '' fastrack not only for one tumor, but for all cancers'', ''incredible ''...

Concerning cancer, he expects the second part of phase 1 trial to start in the first quarter of 2022.

As for NASH, '' no partner yet, will cost $160 millions u.s.''

( rough translation )

''I would prefer having a partner, but we can't sit on a phase 3 protocol too long; we can't do that. It's incredible what we have achieved, we have to go ahead. Partner or not , the study will start in the first part of 2022 '' .

He expects to receive an approval in 5 years.

Again it is a good and positive article.
<< Previous
Bullboard Posts
Next >>